Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 10:02:26 +0200Fri, 12 Jul 2024 14:40:00 +0200Opinion/decision on a Paediatric investigation plan (PIP): Kevzara, sarilumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0258/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001045-pip01-10-m03Opinion/decision on a Paediatric investigation plan (PIP): Kevzara, sarilumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0258/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001045-pip01-10-m03Fri, 12 Jul 2024 14:40:00 +0200Human medicine